| Safety of the recombinant zoster vaccine was evaluated in six clinical trials in immunocompromised adults ≥ 18 years of age |
| Adverse event profiles were generally balanced between the recombinant zoster vaccine and placebo and were generally consistent with the underlying diseases and/or therapies |
| Recombinant zoster vaccine has a favorable benefit-risk profile in adults ≥ 18 years of age with diverse immunocompromising conditions |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.